Qiagen在强劲的销售和收购以及2026年的预计持续增长的推动下,超过了2025年Q4的预期收入。 Qiagen exceeded earnings expectations in Q4 2025, driven by strong sales and acquisitions, and projected continued growth for 2026.

Bio-Techne报告了2026年Q2的固定有机收入,经调整的EPS增加10%至4.46美元,其驱动因素是成本节约和剥离,但总利润因产品组合而下降到68.5%。 Bio-Techne reported flat organic revenue in Q2 2026, with adjusted EPS up 10% to $0.46, driven by cost savings and divestitures, though gross margin declined to 68.5% due to product mix. Qiagen的2025年Q4成绩强劲,销售额为5.4亿美元,经调整的EPS为6.62美元,超过预测,全年销售额为20.9亿美元,按不变汇率增长5%。 Qiagen posted strong Q4 2025 results, with sales of $540 million and adjusted EPS of $0.62, exceeding forecasts, and full-year sales of $2.09 billion, up 5% at constant exchange rates. 关键产品系列、自动化消耗品和收购Parse Bioscience公司推动了增长,该公司自2024年以来向股东退还了11亿美元以上,预测2026年销售额至少增长5%,EPS增长2.50美元。 Growth was fueled by key product lines, automated consumables, and the Parse Biosciences acquisition, with the company returning over $1.1 billion to shareholders since 2024 and projecting at least 5% sales growth and $2.50 EPS for 2026.